Evidence map›Paper›PMID 28331287›Full record

ArticleDrug design, development and therapy2017

Does remifentanil attenuate renal ischemia-reperfusion injury better than dexmedetomidine in rat kidney?

E Erkılıç, E Kesimci, F Alaybeyoğlu, I Kılınç, R Tural, A Yazgan, T Gümüş, A Sepici Dinçel, E G Dumlu, O Kanbak

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07094165 (Evaluation of the Effects of Remifentanil and Dexmedetomidine on Crush Injury and Renal Functions in an Experimental Model), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07094165 nacompletednot on this mapstarted 2024, after this paper: background citation

Evaluation of the Effects of Remifentanil and Dexmedetomidine on Crush Injury and Renal Functions in an Experimental Model

TypeinterventionalSponsorAnkara City Hospital BilkentRan2024 to 2025Enrolled28ConditionsAcute Kidney Injury, Crush Injury, RhabdomyolysisArmsDexmedetomidine, Remifentanil, Laparotomy, Compression
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Opioids and Acute Kidney Injury.Seminars in nephrology · 2021
    Review
  6. Article
  7. In reply: Why remifentanil?Journal of anesthesia · 2018
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

E ErkılıçAnesthesiology and Reanimation Department.
E KesimciAnesthesiology and Reanimation Department.
F AlaybeyoğluAnesthesiology and Reanimation Department.
I KılınçGeneral Surgery Department, Atatürk Training and Research Hospital.
R TuralBiochemistry Department, Faculty of Medicine, Gazi University.
A YazganPathology Department, Atatürk Training and Research Hospital.
T GümüşAnesthesiology and Reanimation Department.
A Sepici DinçelBiochemistry Department, Faculty of Medicine, Gazi University.
E G DumluGeneral Surgery Clinic, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey.
O KanbakAnesthesiology and Reanimation Department.
Imation (United States) · USAnkara Yıldırım Beyazıt University · TREducation Training And Research · USGazi University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIschemia-reperfusion (I/R) injury is a common cause of patient morbidity and mortality in the perioperative period. Patients undergoing long-lasting, abdominal, and urogenital surgeries with risk factors such as advanced age, peripheral artery disease, diabetes mellitus, renovascular disease, and congestive heart failure are candidates for acute kidney injury (AKI) due to impaired renal perfusion and decreased functional renal reserve. Pharmacological agents with multiple functions and anti-oxidative and anti-inflammation properties may be promising preventative strategies for AKI. Recently, dexmedetomidine (dex) has been postulated to have renoprotective effects.

objectivesWe aimed to investigate the protective effects of an intravenous anesthetic remifentanil in renal I/R injury in the rat in comparison with dex. MATERIALS AND

methodsA total of 30 Sprague Dawley adult rats were randomly assigned into five groups: the control group (group C, n=6), the sham group (group Sh, n=6, saline-infused rats without I/R injury), the saline group (group S, n=6, saline-infused rats with I/R injury), the remifentanil-treated group (group REM, n=6), and the dexmedetomidine-treated group (group DEX, n=6). The infusions (saline, remifentanil, and dex) were started after anesthesia induction and right nephrectomy and continued until the end of the surgical procedure. In I/R injury groups, the left renal artery and vein were occluded together by a clamp for 30 minutes and reperfusion lasted for 30 minutes. The rats were sacrificed after reperfusion, and the left kidney tissue was harvested. Blood samples were drawn from all animals to evaluate plasma neutrophil gelatinase-associated lipocalin (NGAL) at the beginning, 15 minutes after ischemia, 15 minutes after reperfusion, and 6 hours after the surgical procedure (T0, T1, T2, and T3, respectively).

resultsThe plasma NGAL levels exhibited increase at T1, T2, and T3 compared to the levels at T0 in group S (

conclusionThe NGAL levels and histopathological findings reflected protection by dex against renal I/R injury. However, the same exact results could not be mentioned for remifentanil depending on our study results.

Indexed as

Analgesics, OpioidAnimalsDexmedetomidineInjections, IntravenousKidneyPiperidinesRatsRats, Sprague-DawleyRemifentanilReperfusion InjuryAnalgesics, OpioidDexmedetomidinePiperidinesRemifentanildexmedetomidineischemia–reperfusionneutrophil gelatinase-associated lipocalinremifentanil

Identifiers

PMID28331287
PMCPMC5352155
OpenAlexW2593427867

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.